期刊文献+

高效液相色谱法测定罗氟司特药品中罗氟司特和4种杂质 被引量:3

HPLC Determination of Roflumilast and 4 Impurities in Roflumilast Drug
下载PDF
导出
摘要 提出了高效液相色谱法测定罗氟司特药品中罗氟司特和4种杂质。样品以乙腈溶解,采用Welch Ultimate XB-C18色谱柱为分离柱,以0.01mol·L-1磷酸氢二钾溶液(用磷酸调节pH为4.0)与乙腈以体积比50比50组成的混合溶液为流动相,在检测波长215nm处进行测定。罗氟司特和4种杂质在一定的质量浓度范围内与其峰面积呈线性关系。方法的测定下限(10S/N)在0.04~0.22ng之间。加标回收率在101%~102%之间,测定值的相对标准偏差(n=9)均小于2.0%。 HPLC was applied to the determination of Roflumilast and 4 impurities in Roflumilast drug. The sample was dissolved with acetonitrile. Welch Ultimate XB-C18 chromatographic column was used as stationary phase, and a mixture of 0. 01 mol · L-1 K2HPO4 solution (adjusted pH to 4 with phosphoric acid) and acetonitrile (50+50) was used as mobile phase. UV-detection at 215 nm was adopted in the determination. Linear relationships between values of peak area and mass concentration of Roflumilast and the 4 impurities were kept in definite ranges. Low limits of determination (10S/N) found were ranged from 0. 04 to 0. 22 ng. Values of recovery found by standard addition method were in the range of 101%-102%, and values of RSD's (n=9) less than 2.0%.
出处 《理化检验(化学分册)》 CAS CSCD 北大核心 2015年第5期594-596,共3页 Physical Testing and Chemical Analysis(Part B:Chemical Analysis)
基金 河南省基础与前沿技术研究计划项目资助(132300410478)
关键词 高效液相色谱法 罗氟司特 药品 杂质 HPLC Roflumilast Drug Impurity
  • 相关文献

参考文献9

二级参考文献83

  • 1贺蓓.多中心随机对照临床研究表明Roflumilast可以改善慢性阻塞性肺病患者的肺功能[J].中华医学杂志,2005,85(36):2546-2546. 被引量:1
  • 2彭国平,吴盘华,李红阳,袁永泰.补骨脂化学成分的研究[J].中药材,1996,19(11):563-565. 被引量:30
  • 3RABE KF. Roflumilast for the treatment of chronic obstructive pulmonary disease [ J ]. Expert Rev Respir Med, 2010, 4 ( 5 ) : 543 -555.
  • 4RABE KF, HURD S, ANZUETO A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary [ J ]. Am Respir Crit Care Med, 2007,176 ( 6 ) : 532 - 555.
  • 5MANNINO DM, HOMA DM, AKINBAMI LJ, et al. Chronic ob- structive pulmonary disease surveillance: United States, 1971 - 2000[J]. MMWR CDC Surveill Summ, 2002, 51 (6) :1 - 16.
  • 6HATZELMANN A, MORCILLO EJ, LUNGARELLA G, et al. The preclinical pharmacology of roflumilast: a selective, oral phosphodiesterase inhibitor in development for chronic obstructive pulmonary disease[ J ]. Pulm Pharmacol Ther, 2010, 23 (4) : 235 -256.
  • 7PRESS NJ, BANNER KH. PDE4 inhibitors-a review of the current field[ J]. Prog Med Chem, 2009, 47 (1) :37 -74.
  • 8WOHLSEN A, HIRRLE A, TENOR H, et al. Effect of cyclic AMP elevating agents on airway ciliary beat frequency in central and lateral airways in rat precision-cut lung slices [ J ]. Eur J Pharmacol, 2010, 635 ( 1 - 3 ) : 177 - 183.
  • 9CHAPMAN RW, HOUSE A, JONES H, et al. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats [ J ]. Eur J Pharmacol, 2007, 571 (2 - 3) :215 -221.
  • 10HOHLFELD JM, SCHOENFELD K, LAVAE-MOKHTARI M, et al. Roflumilast attenuates pulmonary inflammation upon segmen- tal endotoxin challenge in healthy subjects: a randomized place- bocontrolled trial [ J ]. PulmPharmacol Ther, 2008, 21 ( 4 ) : 616 - 625.

共引文献35

同被引文献20

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部